PPARγ agonists and PGC-1α exhibit a wide range of activities that positively influence the pathology of PD in experimental models, and they have the capacity to be neuroprotective by regulating the expression of genes involved in neuronal survival processes. Here, PPARG is linked to Parkinson disease.